COMMUNIQUÉS West-GlobeNewswire

SkinnyRx GLP-1 Claims Evaluated: Review Semaglutide & Tirzepatide Weight Loss Medication Options with Clinician-Guided Care
23/04/2026
Semaglutide and tirzepatide telehealth access, compounded GLP-1 program pricing, refund terms, and weight loss medication overview for 2026 Sacramento, CA, April 23, 2026 (GLOBE NEWSWIRE) -- The information below [...]
Denta Biome Under Investigation: Adem Naturals Chewable Dental Tablets for Oral Health Care Support
23/04/2026
A 2026 informational overview of Denta Biome chewable dental tablets, oral postbiotic science, FabM enzyme research context, gum health and bad breath ingredient analysis, pricing structure, and consumer verification [...]
Kane Biotech Announces Fourth Quarter and Full Year 2025 Financial Results
24/04/2026
WINNIPEG, Manitoba, April 23, 2026 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (the “Company”, “Kane” or “Kane Biotech”) announces today its fourth quarter and full year 2025 financial results. Full Year 2025 [...]
Agomab Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
24/04/2026
-- Cash and Cash Investments at December 31, 2025 of €116.5 Million and Gross Proceeds of $208 Million from Initial Public Offering (IPO) Expected to Extend Cash Runway into First Half of 2029 -- -- Positive [...]
Grace Therapeutics Provides Regulatory Update on New Drug Application for GTx-104
23/04/2026
FDA Issued Complete Response Letter Citing Outstanding Items Related to Chemistry, Manufacturing, and Controls and Non-Clinical Information FDA Does not Request Additional Clinical Data Company Intends to Resubmit [...]
Coloplast A/S - Coloplast revises financial guidance for FY 2025/26 to reflect reduced growth outlook for Kerecis
23/04/2026
Announcement no. 04/2026 Inside information Coloplast revises the financial guidance on organic growth and EBIT growth in constant currencies before special items for FY 2025/26, reflecting a slower market recovery in [...]
Progyny, Inc. Announces Details for Its First Quarter 2026 Results Report
23/04/2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a global leader in women’s health and family building solutions, will report its financial results for the quarterly period ended March 31, 2026 [...]
Hormify Launches Transparent, Research-Based Supplement for Hormonal Balance and Daily Wellness
23/04/2026
NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Hormify today announced the introduction of its transparent, research-based dietary supplement formulated to support hormonal balance, mood, and energy. Produced in FDA- [...]
This Alcohol Awareness Month, Oxford Treatment Center Raises Red Flag, Citing Significant Rise in Patients Seeking Help for Alcohol Addiction
23/04/2026
ETTA, Miss., April 23, 2026 (GLOBE NEWSWIRE) -- With April designated as Alcohol Awareness Month, Oxford Treatment Center, a leading provider of addiction and co-occurring disorder treatment in Mississippi, is sounding [...]
Regeneron Announces Agreement with U.S. Government to Help Lower Drug Costs for American Patients and Will Provide Innovative New Gene Therapy for Free in the U.S.
23/04/2026
Regeneron will provide Otarmeni™ (lunsotogene parvec-cwha) , its recently approved gene therapy for an ultra-rare form of genetic hearing loss, for free in the U.S. Regeneron will lower Medicaid prices based on prices [...]
GUERBET : Nombre d'actions et de droits de vote composant le capital de la société au 31 mars 2026
23/04/2026
DECLARATION RELATIVE AU NOMBRE DE DROITS DE VOTE ET D'ACTIONS COMPOSANT LE CAPITAL DE LA SOCIETE En application de l'article L. 233-8 II du code de commerce et de l’article 222-12-5 du règlement général de l’AMF, les [...]
Otarmeni™ (lunsotogene parvec-cwha) Approved by FDA as First and Only Gene Therapy for Genetic Hearing Loss; Regeneron to Provide Otarmeni for Free in the U.S.
23/04/2026
Approval in severe-to-profound and profound OTOF -related hearing loss is based on pivotal results of the CHORD trial demonstrating 80% of participants achieved or surpassed a hearing level meeting the primary endpoint [...]
PridCor Therapeutics Secures Global Antiviral Portfolio, Establishing Leadership in Treatment of Long COVID and Infection-Associated Chronic Illnesses
23/04/2026
TUSCALOOSA, Ala., April 23, 2026 (GLOBE NEWSWIRE) -- PridCor Therapeutics LLC, a clinical-stage biopharmaceutical company, today announced the acquisition of a global antiviral asset portfolio, establishing the Company [...]
First-quarter 2026 revenue
23/04/2026
Press release Revenue as at 31 March 2026 stood at €1 , 336m , up +4.9% on an organic basis compared with the first quarter of 2025 All business segments and regions contributed to revenue growth, supported by [...]
Chiffre d'affaires du 1er trimestre 2026
23/04/2026
Communiqué de presse Le chiffre d’affaires au 31 mars 2026 s’établit à €1 336m , en progression de +4,9% en base organique par rapport au 1 er trimestre 2025 L’ensemble des activités et des régions contribue à la [...]
IMAAVY® (nipocalimab)▼shows over two years of sustained disease control in a broad population with generalised myasthenia gravis (gMG)
23/04/2026
Through 120 weeks of follow-up, nipocalimab delivered sustained clinical improvements and reductions in total IgG in antibody-positive adult patients including anti-AChR+ and anti-MuSK+ Patients achieving sustained [...]
Q1 2026 revenue
23/04/2026
Q1 2026 revenue Quarterly activity Revenue: €177.4m, up 2.6% at CER 1 and on a like-for-like basis 2 Increase driven by EMEA (+4.5%), with an improvement in the situation in France, and by Asia (+6.0%); a decline in the [...]
Orchestra BioMed to Present AVIM Therapy Clinical and Mechanistic Data at HRS 2026
23/04/2026
Pre-randomization Atrioventricular Interval Modulation Therapy (“AVIM Therapy”) set-up data from the MODERATO II randomized, prospective, multi-center, double-blind, controlled trial show an immediate average reduction [...]
FSR, in Partnership with ATS, Welcomes Dr. Matt Craig to Drive Strategic Research Initiatives
23/04/2026
CHICAGO, April 23, 2026 (GLOBE NEWSWIRE) -- Through the long-standing collaboration between Foundation for Sarcoidosis Research (FSR) and the American Thoracic Society (ATS), FSR and ATS are pleased to announce that [...]

Pages